Anaplastic Astrocytoma Drug Market to Witness Robust Expansion by 2028
The global anaplastic astrocytoma drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Anaplastic astrocytoma is a rare type of brain tumor that starts from brain cells called astrocytes. Astrocytes are a type of glial cell. Additionally, it is both a type of astrocytoma and high-grade glioma. The major factor driving the growth of the market is the increasing prevalence of anaplastic astrocytoma across the globe.
According to the National
Organization for Rare Diseases, astrocytomas are the most common primary brain
tumors. It affects males more often than females and is estimated to affect 5-8
people per 100,000 in the general population. Additionally, anaplastic
astrocytomas are more common in adults than children and usually develop
between 30 and 50 years of age in adults. Furthermore, anaplastic astrocytomas
usually develop between 5 and 9 years of age in children and account for
approximately 10% of childhood central nervous stem tumors. Moreover, approximately
80% of astrocytomas in children are low grade. Hence, the increasing prevalence
of anaplastic astrocytoma is driving the demand for anaplastic astrocytoma
drugs for treatment which in turn is driving the growth of the market.
To Request a Sample of our Report on Anaplastic Astrocytoma Drug Market: https://www.omrglobal.com/request-sample/anaplastic-astrocytoma-drug-market
Some major players in the market
include Amgen Inc, Astellas Pharma Inc., and Bayer AG, among others. The market
players are contributing significantly to the growth of the market by the
adoption of various strategies including mergers & acquisitions,
geographical expansion, partnerships and collaborations, and new product
launches, to stay competitive in the market. For instance, in January 2021,
Adastra Pharmaceuticals, Inc. announced the completion of the Phase 1b clinical
trial conducted by the NCI with its lead clinical candidate zotiraciclib
(ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor. The trial
was aimed to investigate the safety and efficacy of ZTR in combination with
temozolomide (TMZ) in patients with recurrent high-grade gliomas.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
Segment Covered-
·
By Type
·
By Application
Regions Covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
Competitive Landscape- Amgen Inc, Astellas Pharma
Inc., and Bayer AG, among others.
A
full Report of Anaplastic Astrocytoma Drug Market is Available @ https://www.omrglobal.com/industry-reports/anaplastic-astrocytoma-drug-market
Global Anaplastic Astrocytoma Drug Market Report by
Segment
By Type
•
A-10
•
AS-21
•
AdRTSIL-12
•
ADU-623
•
Others
By Application
•
Hospital
•
Clinic
•
Others
Global Anaplastic Astrocytoma Drug Market Report by
Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment